Inventiva (NASDAQ:IVA) Upgraded at Truist Financial

Inventiva (NASDAQ:IVA) was upgraded by Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other research analysts have also commented on the company. UBS Group initiated coverage on Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 price objective on the stock. Guggenheim decreased their target price on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Barclays initiated coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Finally, HC Wainwright set a $24.00 target price on shares of Inventiva and gave the stock a “buy” rating in a report on Wednesday, January 28th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Stock Performance

Inventiva stock opened at $6.04 on Wednesday. Inventiva has a 1-year low of $2.70 and a 1-year high of $7.98. The firm’s fifty day simple moving average is $6.28 and its 200-day simple moving average is $5.36.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IVA. Wealth Enhancement Advisory Services LLC lifted its position in Inventiva by 55.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the period. Creative Planning bought a new stake in Inventiva in the 2nd quarter valued at $32,000. Commonwealth Equity Services LLC raised its stake in shares of Inventiva by 19.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Inventiva in the 4th quarter valued at $60,000. Finally, XTX Topco Ltd bought a new position in shares of Inventiva during the 4th quarter worth about $84,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.